MK-4 and MK-7 are both forms of vitamin K2, but they behave so differently in the body that comparing them is a bit like comparing a quick-release painkiller to an extended-release one. MK-4 surges into the bloodstream fast and disappears within hours, while MK-7 lingers for days, building up steady levels over time. Which one is “better” depends entirely on what you are trying to accomplish, and the research behind each form tells a more complicated story than supplement marketing usually lets on.
How They Move Through Your Body
The single biggest difference between MK-4 and MK-7 is how long they stick around after you take them. When researchers gave healthy women equal amounts of vitamin K1, MK-4, and MK-9 (a longer-chain form similar to MK-7), MK-4 peaked quickly but had a short half-life and a small total exposure compared to the other forms.1PubMed Central. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women In a separate study looking at equimolar doses, MK-4’s peak blood concentration reached only about 39% of vitamin K1’s peak, and it appeared in the blood earlier. MK-7, by contrast, has a plasma half-life of roughly three days, and at the same daily intake it produces blood concentrations around five times higher than those for vitamin K1.2Journal of Lipid Research. Metabolism of vitamin K: a decade of advances
In plain terms, MK-4 is in and out quickly. If you take it once a day, your blood levels of the vitamin spike and then drop back to near zero before your next dose. MK-7 accumulates gradually, maintaining a more consistent baseline. This pharmacokinetic gap is the reason MK-4 is typically dosed at much higher amounts, often 15 mg three times a day in Japanese clinical protocols, while MK-7 supplements commonly contain just 100 to 200 micrograms taken once.
Your Body Makes MK-4 on Its Own
Here is something that surprises most people: your body converts other forms of vitamin K into MK-4 regardless of what form you eat. Researchers identified the enzyme responsible, called UBIAD1, and found that the conversion pathway involves the intestine stripping the side chain off vitamin K1 to produce menadione, which then circulates to tissues and gets rebuilt as MK-4.3PubMed Central. Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis This means that even if you never take an MK-4 supplement, your brain, kidneys, and other organs contain MK-4 derived from the vitamin K1 in leafy greens.
MK-7, on the other hand, is not something the body manufactures. It comes almost exclusively from bacterial fermentation, either in foods like natto (a traditional Japanese fermented soybean dish) or in manufactured supplements. Because MK-7 reaches tissues through circulation rather than local conversion, its long half-life matters more practically: it can travel widely through the bloodstream at sustained concentrations. MK-4’s tissue presence depends more on local conversion than on what the blood level looks like at any given moment. This partly explains why oral MK-4 at microgram-level doses barely registers in serum, yet MK-4 is the dominant form found in most human tissues.
How They Interact With the Vitamin K Cycle
Both MK-4 and MK-7 do their work by feeding into the vitamin K cycle, the enzyme loop that activates proteins involved in blood clotting, bone building, and calcium regulation. But they do not feed into it equally well at the molecular level. Computational and laboratory work examining how the enzyme VKORC1 handles different vitamin K forms found that it binds vitamin K1 and MK-4 tightly and processes them with equivalent activity. MK-7, however, showed weaker binding, partly because its long hydrophobic tail interferes with how it sits in the enzyme, and VKORC1’s activity toward MK-7 was much lower.4Nutrients. Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1
This does not mean MK-7 is ineffective. Its sustained blood levels compensate for its weaker per-molecule enzyme interaction. But it does suggest that comparing the two forms milligram-for-milligram misses the point. They arrive at the same biological result through different routes: MK-4 through high tissue affinity and tight enzyme binding, MK-7 through persistent circulation and gradual delivery.
Bone Health Evidence
Bone health is the area where both forms have been studied most, and the results are frustratingly mixed. The overall pattern from a recent systematic review is that clinical findings on K2 for bone mineral density and fractures are inconsistent. Pharmacologic-dose MK-4 reduced fractures in some Japanese cohorts, while low-dose MK-7 yielded site-specific effects in some trials and null results in others. Studies outside Japan often showed no significant benefits for either form.5Frontiers in Endocrinology. The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis
That said, a few individual MK-7 trials stand out. A three-year Dutch trial of 180 micrograms daily in healthy postmenopausal women found that MK-7 significantly reduced the age-related decline in bone mineral content and density at the lumbar spine and femoral neck, and improved bone strength, though it had no effect at the total hip.6PubMed. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women Another study using 375 micrograms of MK-7 for 12 months in postmenopausal women with low bone density found that trabecular bone structure at the tibia was preserved in the MK-7 group while it deteriorated in the placebo group.7European Journal of Endocrinology. Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women
A Chinese randomized controlled trial of 90 micrograms of MK-7 daily found reduced bone loss at the femoral neck in postmenopausal women compared to placebo, but no effect in men. Interestingly, adding calcium and vitamin D3 on top of the MK-7 brought no extra benefit, suggesting MK-7 was doing its own independent work.8PubMed. Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study
MK-4’s bone evidence rests largely on Japanese research using high pharmacological doses of 45 mg per day, a dose hundreds of times greater than what you find in a typical MK-7 supplement. At that level, some Japanese studies reported fracture reductions, which is why MK-4 at 45 mg/day is approved as an osteoporosis treatment in Japan. But those results have not reliably replicated in Western populations, leaving the bone story without a clean winner between the two forms.
Cardiovascular Calcification
One of the most promising applications for vitamin K2 in recent years is slowing the buildup of calcium in arteries, a process linked to heart disease risk. A key mechanism here involves a protein called matrix Gla protein, which needs vitamin K to become activated and do its job of keeping calcium out of soft tissues. Lab research has confirmed that vitamin K2 can inhibit the calcification of vascular smooth muscle cells by restoring a protective signaling pathway that blocks cell death in blood vessel walls.9PubMed. Vitamin K2 inhibits rat vascular smooth muscle cell calcification by restoring the Gas6/Axl/Akt anti-apoptotic pathway
The strongest human trial on this front used MK-7. A large double-blind placebo-controlled trial called DANCODE enrolled 400 patients with severe coronary artery calcification and gave them either 720 micrograms of MK-7 plus vitamin D3 or placebo for two years. The supplemented group’s coronary calcium scores increased by an average of 196 Agatston units, compared to 248 in the placebo group, a significant reduction of about 52 units in calcification progression. The reduction came without any increase in dangerous noncalcified plaque.10Circulation. Vitamin K2 and D3 Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE Trial This is the kind of result cardiologists pay attention to, and it was achieved with MK-7 rather than MK-4.
No comparable large-scale cardiovascular trial exists for MK-4. That does not prove MK-4 would not work in this context, but it does mean the cardiovascular evidence currently favors MK-7.
The Vitamin D Connection
You will often see vitamin K2 and vitamin D sold together, and there is a reasonable scientific basis for it. Both vitamins influence calcium metabolism, and evidence from animal and human studies suggests that having adequate levels of both is more beneficial for bone and cardiovascular health than having adequate levels of just one.11International Journal of Endocrinology. The Synergistic Interplay between Vitamins D and K for Bone and Cardiovascular Health: A Narrative Review The logic is straightforward: vitamin D increases the production of proteins like osteocalcin and matrix Gla protein, but those proteins need vitamin K to become functional. Without enough K2, you may produce plenty of these calcium-regulating proteins but leave them sitting around in their inactive form.
The DANCODE trial mentioned earlier used MK-7 with vitamin D3, and the fact that it showed measurable effects on coronary calcification lends some real-world weight to the combined approach.10Circulation. Vitamin K2 and D3 Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE Trial Whether MK-4 would pair equally well with vitamin D in this setting remains untested in large human trials.
Blood Sugar and Metabolic Health
A newer and more surprising line of research connects MK-7 supplementation to improvements in blood sugar control. A study in people with type 2 diabetes found that MK-7 intervention led to notable reductions: about 13% in fasting blood glucose, roughly 28% in fasting insulin, and about 7% in HbA1c (a marker of long-term blood sugar). Mice with diet-induced obesity also showed significant improvement in glucose tolerance.12BMC Medicine. Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites The researchers attributed the effect partly to changes in the gut microbiome. This is still early-stage evidence, and the effect sizes are striking enough that replication in larger trials is needed before drawing firm conclusions. But it adds a metabolic dimension to MK-7’s profile that MK-4 research has not matched.
The Warfarin Problem
If you take warfarin or another vitamin K antagonist anticoagulant, the MK-4 versus MK-7 question takes on a very different and more urgent dimension. Warfarin works by blocking the vitamin K cycle, so adding any form of vitamin K can interfere with your dose. But MK-7’s long half-life makes it particularly problematic. A study in healthy volunteers found that just 10 micrograms of daily MK-7, far below the typical supplement dose, caused a clinically relevant lowering of INR (the standard measure of anticoagulant effect) in at least 40% of subjects. At 20 micrograms, that figure rose to 60%. At 45 micrograms, the group average INR dropped by about 40%. The researchers concluded that MK-7 supplements should be avoided entirely in patients on vitamin K antagonist therapy.13PubMed. Effect of low-dose supplements of menaquinone-7 (vitamin K2 ) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers
Separate analysis of patients on anticoagulant therapy confirmed that MK-7 concentrations and total vitamin K levels were significantly associated with baseline INR values, reinforcing the real-world clinical relevance of this interaction.14PubMed Central. The investigation of connection between anticoagulant therapy and vitamin K homologues in human determined by LC-MS/MS
MK-4, with its rapid clearance, poses a theoretically smaller risk of sustained INR disruption simply because it does not accumulate the way MK-7 does. But “smaller risk” is not the same as “safe,” and anyone on warfarin should treat all vitamin K2 supplements as potentially dangerous without close medical supervision.
Safety in the General Population
For people not on anticoagulants, both forms have reassuring safety profiles. Toxicology testing of synthetic MK-7 in animals found no adverse effects at the highest doses tested, and the lethal dose in mice exceeded 2,000 mg per kilogram of body weight, an enormous amount relative to supplement doses.15PubMed Central. Safety and toxicological evaluation of a synthetic vitamin K2, menaquinone-7 A review by the US Pharmacopeial Convention concluded that MK-7 as a dietary supplement is not associated with any serious risk to health.16Nutrition Reviews. US Pharmacopeial Convention safety evaluation of menaquinone-7, a form of vitamin K MK-4 has a similarly clean safety record, in part because it clears the body so quickly that accumulation to toxic levels is essentially impossible at normal supplement doses.
The Natto Factor
Natto, the sticky fermented soybean food eaten regularly in parts of Japan, is the richest natural source of MK-7. A meta-analysis of Japanese evidence found that habitual natto consumption was associated with substantially elevated serum MK-7 levels, increased total osteocalcin (a bone-building marker), decreased undercarboxylated osteocalcin (the inactive form, which you want low), and modestly greater bone mineral density across multiple sites.17Frontiers in Nutrition. Habitual natto intake elevates serum MK-7 levels, enhances osteocalcin carboxylation, and supports bone density: a meta-analysis of Japanese evidence This dietary pattern is sometimes cited as evidence that MK-7 is the “natural” choice, but it is worth noting that natto consumption is a distinctly regional habit. Most of the world’s population gets its vitamin K2 through MK-4 in animal products like egg yolks, butter, and organ meats, or through the body’s own conversion of K1.
Supplement Quality Is Not Uniform
One practical concern that rarely makes it into the MK-4 versus MK-7 debate is product stability. Research comparing different MK-7 raw materials found that the purity of the starting ingredient directly affected how well the vitamin held up over time. Higher-purity MK-7 was more stable under both normal and accelerated storage conditions, and this variability could explain discrepancies in the actual vitamin K2 content of finished products sold worldwide.18Molecules. Menaquinone 7 Stability of Formulations and Its Relationship with Purity Profile In other words, the MK-7 supplement on one shelf may deliver meaningfully less active vitamin than the one next to it, even if the label claims are identical. MK-4 is a simpler, more chemically stable molecule, which may give it a slight practical edge in terms of what you actually get versus what the label says.
During Pregnancy and Early Life
Vitamin K2 plays a role during pregnancy and infancy that is easy to overlook. Research on MK-4 specifically found that while the placenta actively takes up MK-4 from the mother’s blood, the transfer to fetal circulation is slow: the vitamin appears to be stored in the placenta and released gradually. After delivery, MK-4 given to mothers concentrated in breast milk even after blood levels in the mother had dropped, suggesting the mammary gland actively accumulates it.19PubMed. Pharmacokinetics of vitamin K in mothers and children in the perinatal period: transplacental transport of vitamin K2 (MK-4) This built-in concentrating mechanism for MK-4, rather than MK-7, in reproductive tissues hints at a biological preference for the shorter-chain form in early development, though the clinical significance is still being explored.
Choosing Between Them in Practice
If you are looking for cardiovascular calcification protection, the trial evidence currently points toward MK-7, ideally paired with vitamin D3, given that the strongest human trial used that combination. If you live in Japan or have access to pharmacologic-dose MK-4 through a healthcare provider, MK-4 at 45 mg/day has a track record for fracture reduction in specific populations, though that dose level is not commonly available as an over-the-counter supplement in most countries. For general bone health maintenance, low-dose MK-7 in the range of 90 to 375 micrograms daily has the most accessible positive trial data in postmenopausal women.
Some people take both forms, and there is no known harm in doing so for the general population. The two forms work through partially different pathways: MK-4 through high tissue affinity and local conversion, MK-7 through sustained circulation. They are not competing for the same biological niche so much as covering complementary ground. The one group that should avoid this entirely, or any K2 supplementation without medical oversight, is people on warfarin or similar vitamin K antagonist drugs, where even tiny amounts of MK-7 can throw off anticoagulation control.
What the evidence does not yet support is the common marketing claim that one form is universally superior. MK-7 has more convenience going for it (one small daily dose, long half-life, strong cardiovascular data). MK-4 has deeper biological roots in human tissues and a distinct pharmacological profile at high doses. The honest answer is that the “better” form depends on why you are taking it, what dose you can access, and whether you are on medications that interact with vitamin K.